Division of Cardiothoracic Imaging, Department of Medical Imaging, University Health Network, Toronto General Hospital, University of Toronto, 585 University Ave., Toronto, ON, M5G 2N2, Canada.
Int J Cardiovasc Imaging. 2013 Oct;29(7):1517-26. doi: 10.1007/s10554-013-0249-z. Epub 2013 Jun 4.
The purpose of this study is to examine the effect of different iron chelation regimens on the distribution of myocardial iron in patients with transfusion-dependent anemias. Institutional review board approval was obtained. Patients treated with iron chelation therapy who had undergone baseline and 1-year follow-up cardiac T2* MR studies in a four-year period were identified retrospectively. One hundred and eight patients (44 % male, mean age 31.6 ± 9.7 years) were included. The interventricular septum on three short-axis slices (basal, mid and apical) was divided into anterior and inferior regions of interest for T2* analysis. Cardiac iron concentration (CIC) was calculated from T2* values. Statistical analysis included analysis of variance and paired t-test, using Bonferroni adjustment in all pairwise comparisons. At baseline, T2* measurements varied significantly across all six regions (p < 0.001): lowest in the mid anteroseptum (mean 22.3 ± 10.1 ms) and highest in the apical inferoseptum (mean 26.2 ± 12.8 ms). At follow-up, T2* and CIC values improved significantly in all segments [mean change of 3.78 ms (95 % CI (2.93, 4.62), p < 0.001) and 0.23 mg/g (95 % CI (0.16, 0.29), p < 0.001), respectively]. Change in T2* values varied significantly between segments (p < 0.001) with greatest improvement in the apical inferoseptum [4.26 ms, 95 % CI (2.42, 6.11)] and least improvement in the basal anteroseptum [2.95 ms, 95 % CI (1.37, 4.54)]. The largest improvement in T2* values was noted in patients treated with deferiprone [4.96 ms, 95 % CI (2.34, 7.58)]. There was a statistically significant difference in improvement in CIC values between chelation regimens (p = 0.016). This is the first study to report heterogeneity in response to iron chelating drugs with variable segmental changes in T2* values.
这项研究的目的是探讨不同铁螯合方案对依赖输血的贫血患者心肌铁分布的影响。本研究获得了机构审查委员会的批准。通过回顾性分析,确定了在四年期间接受基线和一年心脏 T2MR 随访研究的接受铁螯合治疗的患者。共纳入 108 例患者(44%为男性,平均年龄 31.6±9.7 岁)。三个短轴切片(基底、中间和心尖)的室间隔被分为前间隔和下间隔感兴趣区用于 T2分析。心脏铁浓度(CIC)根据 T2值计算。统计分析包括方差分析和配对 t 检验,所有两两比较均采用 Bonferroni 调整。基线时,所有六个区域的 T2测量值差异有统计学意义(p<0.001):中隔前间隔最低(平均值 22.3±10.1ms),心尖下间隔最高(平均值 26.2±12.8ms)。随访时,所有节段的 T2和 CIC 值均显著改善[平均变化分别为 3.78ms(95%CI(2.93,4.62),p<0.001)和 0.23mg/g(95%CI(0.16,0.29),p<0.001)]。节段间 T2值的变化差异有统计学意义(p<0.001),心尖下间隔改善最大[4.26ms,95%CI(2.42,6.11)],基底前间隔改善最小[2.95ms,95%CI(1.37,4.54)]。用去铁酮治疗的患者 T2值改善最大[4.96ms,95%CI(2.34,7.58)]。不同螯合方案的 CIC 值改善程度存在统计学差异(p=0.016)。这是第一项报道铁螯合剂治疗反应存在异质性的研究,T2值的节段性变化不同。